Table 1

Baseline clinical and treatment characteristics of the participants

VariablesNCTHF (n=894)CTHF (n=75)P values
Age, years55.6±13.648.2±14.1<0.001
Male, n (%)628 (70)26 (35)<0.001
White, n (%)751 (84)61 (81)0.55
Body mass index, kg/m2 28.8±6.126.6±5.70.003
NYHA, n (%)0.50
 I265 (30)28 (37)
 II312 (35)22 (29)
 III265 (30)22 (29)
 IV52 (6)3 (4)
Ischaemic cardiomyopathy, n (%)224 (25)4 (5)<0.001
Hypertension, n (%)538 (60)26 (35)<0.001
Diabetes mellitus, n (%)239 (27)11 (15)0.022
Coronary artery disease, n (%)325 (36)17 (23)0.017
Atrial fibrillation, n (%)306 (34)14 (19)0.006
COPD, n (%)88 (10)5 (7)0.37
Chronic kidney disease, n (%)247 (28)17 (23)0.35
Anaemia, n (%)233 (26)18 (24)0.70
LVEF, %30 [20, 40]40 [26, 50]<0.001
LVEF categories0.005
 <40%, n (%)594 (66)36 (48)
 40%–49%, n (%)126 (14)18 (24)
 ≥50%, n (%)174 (20)21 (28)
Recovered LVEF, n (%)164 (18)21 (28)0.041
CRT/ICD, n (%)391 (44)16 (21)<0.001
Pacemaker, n (%)411 (46)20 (27)0.001
Beta-blocker, n (%)770 (86)52 (69)<0.001
ACEI/ARB, n (%)710 (79)53 (71)0.08
Aldosterone antagonist, n (%)259 (29)21 (28)0.86
Diuretic, n (%)607 (68)39 (52)0.005
Calcium channel blocker, n (%)70 (8)5 (7)0.72
Anticoagulation, n (%)316 (35)18 (24)0.047
Antiplatelet, n (%)477 (53)19 (25)<0.001
Antiarrhythmic, n (%)290 (32)20 (27)0.30
Statin, n (%)439 (49)30 (40)0.13
  • Data are presented as mean±SD for normally distributed variables and median [25th, 75th percentiles] for non-normally distributed continuous variables.

  • ACEI/ARB, ACE inhibitor or angiotensin receptor blocker; COPD, chronic pulmonary obstructive disease; CTHF, cancer therapy-induced heart failure; CRT/ICD, cardiac resynchronisation therapy and/or implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NCTHF, non-cancer therapy-induced heart failure; NYHA, New York Heart Association Classification.